Follow the 한미약품 share price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 한미약품 has recorded 118 insider filings. Market capitalisation: €4,368.3bn. The latest transaction was filed on 2 July 2026 (Mixed). Among the most active insiders: 국민연금공단. All data is openly available.
117
Insider Decl.
n/a
Thresholds
n/a
63 ops.
Buy Volume
n/a
18 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 한미약품 Strong Buy (bullish), based on 12 analysts. Average price target: ₩599,167.
17Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 12,253 of 29,062 companies
56.0
score / 100
Value
40
Quality
72
FCF yld1.5%
Earn yld2.7%
EV/EBITDA20.3x
ROE16%
Gross mgn57%
Net mgn11%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Hanmi Pharmaceutical es una empresa farmacéutica surcoreana centrada en la investigación y el desarrollo de medicamentos innovadores. Cotiza en la XKRX.